The Metabolic Syndrome and Risk of Prostate Cancer in Italy

PurposeTo provide information on the role of the metabolic syndrome on prostate cancer risk.MethodsWe examined data from a multicentric Italian case-control study. Cases were 1294 patients with incident, histologically confirmed prostate cancer. Controls were 1451 men hospitalized with acute, non-neoplastic conditions. All subjects were younger than 75 years. The metabolic syndrome was defined according to selected indicators of abdominal obesity, hypercholesterolemia, hypertension, and diabetes. We computed multivariate odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression.ResultsConsidering separate components of the metabolic syndrome, the ORs were 0.98 (95% CI, 0.72–1.34) for diabetes, 1.14 (95% CI, 0.96–1.36) for hypertension, 1.54 (95% CI, 1.26–1.89) for hypercholesterolemia, and 1.02 (95% CI, 0.86–1.21) for abdominal obesity. The OR of prostate cancer was 1.66 (95% CI, 1.22–2.28) in men with metabolic syndrome compared with those without. We found ORs of 1.02 (95% CI, 0.83–1.26) for men with one component of the metabolic syndrome, 1.12 (95% CI, 0.89–1.42) for two, 1.65 (95% CI, 1.15–2.36) for three, and 3.99 (95% CI, 1.03–15.4) for four compared with no components.ConclusionsThe metabolic syndrome was associated with the risk of prostate cancer in this population.